508.460.8822 Contact Us

Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design

European Journal of Pharmaceutical Sciences35(5):418-426 (September 2008).

Guo CaStine KJbKauffman JFaDoub WHa.
Corresponding author: changning.guo@fda.hhs.gov

aDivision of Pharmaceutical Analysis, U.S. Food and Drug Administration, 1114 Market Street, Room 1002, St. Louis, MO 63101, United States
bDepartment of Chemistry and Biochemistry and Center for Nanoscience, University of Missouri at St. Louis, 315 Benton Hall, One University Boulevard, St. Louis, MO 63121, United States

Abstract

The purpose of the research was to investigate the influences of actuation parameters and formulation physical properties on nasal spray delivery performance using design of experiment (DOE) methodology. A 3-level, 4-factor Box-Behnken design with a total of 27 experimental runs was used in this study. Nine simulated aqueous formulations with different viscosities and surface tensionswere prepared using carboxymethylcellulose sodium (CMC, gelling agent) and Tween80 (surfactant) each at three concentration levels. Four factors, actuation stroke length, actuation velocity, concentration of gelling agent, and concentration of surfactant were investigated for their influences on measured responses of shot weight, spray pattern, plume geometry and droplet size distribution (DSD). The models based on data from the DOE were then optimized by eliminating insignificant terms. Pfeiffer nasal spray pump units filled with the simulated formulations were used in the study. Nasal pump actuation stroke length exerts a strong, independent influence on shot weight, and also slightly affects spray pattern and plume geometry. Actuation velocity and concentration of gelling agent have significant effects on spray pattern, plume geometry and DSD, in a complicated manner through interaction terms. Concentration of surfactant has little, if any, influence on nasal spray characteristics. Results were fitted to quadratic models describing the inherent relationships between the four factors evaluated and nasal spray performance. The DOE study helped us to identify the source of variability in nasal spray product performance, and obtained better understanding in how to control the variability. Moreover, the quadratic models developed from the DOE study quantitatively describe the inherent relationships between the factors and nasal spray performance characteristics. With the assistance of the response surfaces developed from the DOE model, the time and labor in designing a nasal spray product to achieve desired product performance characteristics can be reduced.

PMID: 18832029 [PubMed – indexed for MEDLINE]

 

Filter publications by

DDL2019
December 11, 2019 | Edinburgh, Scotland
MVIS Symposium
October 7, 2019 | Lund, Sweden
Inhalation Asia 2019
November 13, 2019 | Hong Kong

View all upcoming events

 
"Proveris Scientific Corporation provides expert support for nasal developers. They are fast, reliable and are professionals at installing of their equipment and supports in demanding challenges." Dr. Peter Svete, Head of Physical Analytics, Lek Pharmaceuticals d.d.
 
 
"Proveris provides insightful and thorough test services. We would recommend working with Proveris. Proveris has great expertise in spray analysis." Elaine Schutte, Chief Development Officer, ProFibrix
 
 
"I want to express my sincere gratitude towards Proveris and the service team for being there to make sure our study goes well. The study just completed few minutes ago and thankfully everything went well.......while we conducted SAC study. It was a great display of professionalism by Proveris." ,
 
 
"As customary, Proveris's service team provided excellent service and was able to answer my questions." ,
 
 
"Thank you for the thorough training on our new equipment. I wish more companies would implement your hands on approach when it comes to training. Thanks again." ,
 
 
“We really appreciate the creativity and work conducted at Proveris for their Test Services (Proveris by Design®). Their knowledge, experience, and insight with OINDP’s was very helpful. Thanks to the Proveris team, we have a wonderful solution that we can use for commercial products!” Mic Iwashima, NDS Division, Shin Nippon Biomedical Laboratories, Ltd